ITCC Trials and the COVID19 Pandemic
A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
10 year report on the European Paediatric Regulation and its impact on new drugs for children's cancers
Outcome of children and adolescents with central nervous system tumors in phase I trials
Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective
Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study
Implementation of Mechanism of Action biology-driven early drug development for children with cancer
Let’s speed up innovation for children with cancer
Gilles Vassal a,∗,b, Birgit Geoerger c
a Direction de la recherche clinique, Gustave-Roussy, 94805 Villejuif, France
b Université Paris-Sud, faculté de médecine, 94270 Le Kremlin-Bicêtre, France
c Département de cancérologie de l’enfant et de l’adolescent, Gustave-Roussy, 94805 Villejuif, France
Challenges for Children and Adolescents With Cancer in Europe: The SIOP-Europe Agenda
ITCC as part of the SIOP Europe initiative is happy to be associated with essentials papers of fundamental importance. It presents a shared and multidisciplinary vision on how the European pediatric oncology community will reduce inequalities regarding access to best standard of cares for children and adolescents across Europe and improve integration of both clinical and translational research into care, as well as increased access to innovative therapies for patients with life threatening diseases across Euope.
One of the main objectives of ITCC is to accelerate the development of new anti-cancer agents for children and adolescents through collaborative early drug trials within the 47 Pediatric Oncology Departments and the 9 European research laboratories members of ITCC in collaboration with the European clinical study groups such as SIOPEN, EpSSG, IBFM and SIOPE brain tumors.
Gilles Vassal MD, PhD, Edel Fitzgerald MA, Martin Schrappe MD, PhD, Frédéric Arnold MSc, Jerzy Kowalczyk MD, PhD, David Walker BMedSci, BM, BS, Lars Hjorth MD, PhD, Riccardo Riccardi MD, Anita Kienesberger MA, Kathy-Pritchard Jones PhD, FRCP (Edin), Maria Grazia Valsecchi PhD, Dragana Janic MD, PhD, Henrik Hasle MD, PhD, Pamela Kearns PhD, MBChB, FRCPCH, Giulia Petrarulo MA, Francesco Florindi MA, Samira Essiaf MSc, Ruth Ladenstein MD, PhD, MBA, cPM.
Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer
Gilles Vassal, Raphaël Rousseau, Patricia Blanc, Lucas Moreno, Gerlind Bode, Stefan Schwoch, Martin Schrappe, Jeffrey Skolnik, Lothar Bergman, Mary Brigid Bradley-Garelik, Vaskar Saha, Andy Pearson, Heinz Zwierzina
Will the revised class waiver list make it?
Gilles Vassal*, Patricia Blanc, Chris Copland, Andrew Pearson
Institut Gustave Roussy, Villejuif, France (GV)
European Consortium for Innovative Therapies for Children with Cancer, Villejuif, France (GV, AP)
Imagine for Margo, Paris, France (PB)
Centre for English Language Teaching, University of York, UK (CC)
Institute for Cancer Research, London, UK (AP)
* Corresponding author: firstname.lastname@example.org at Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
This article is aslo available on the Lancet Oncology website here